Merck
IRBM and Merck announce new agreement in peptide therapeutics
A new agreement in the peptide therapeutics area between integrated drug discovery company, IRBM, and Merck (which is known as MSD outside the US and Canada) has been announced. Read more
Merck should expect strong sales for two new HIV drugs, says GlobalData
After receiving approval for two HIV drugs, Delstrigo and Pifeltro, Merck should be expecting strong sales but probably unlikely to be at blockbuster levels, according to senior pharma analyst at GlobalData. Read more
Field test assesses whether drones can deliver temp-sensitive medicines
A proof of concept field trial is being performed by AT&T and Softbox in collaboration with Merck to test the viability of using connected payloads and drones to deliver temperature-sensitive medicines. Read more
Merck & InnoCore collaboration could be a step forward in biologics delivery, says GlobalData
The recent collaboration between Merck and InnoCore Pharmaceuticals for the development of a new drug delivery platform that will improve compliance could be a step forward in the delivery of biologics, according to GlobalData Read more
Merck & InnoCore Pharmaceuticals enter cooperation agreement for drug delivery platform
Science and technology company, Merck, has entered into a cooperation agreement with Netherlands-based InnoCore Pharmaceuticals, for a new drug delivery platform that will aim to improve patient compliance. Read more
European Commission approves label change for ulcerative colitis treatment
A label change for MSD’s (known as Merck in the US and Canada) ulcerative colitis (UC) treatment — SIMPONI (golimumab) — has received approval from the European Commission. Read more
Blockchain will be seen in healthcare supply chain first, according to GlobalData
After learning that pharma giant, Merck, has filed for a US patent for a blockchain-based system, GlobalData has been led to believe that the first applications of blockchain will initially be seen in the healthcare supply chain Read more
The top five tweets: From Brexit to effects of AIS — what captured the attention of EPM readers this week?
Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more
Merck enters agreement with HistoCyte Laboratories for distribution of reference products
Science and technology company, Merck, has entered into an agreement with HistoCyte Laboratories, for the distribution of its portfolio of cell line reference products for immunohistochemistry and in situ hybridisation. Read more
Results show promise for PARP-inhibitor combination therapy in prostate cancer
Data has been presented by AstraZeneca and Merck demonstrating clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a standard of care Read more
Merck collaborates with Solvias for new test for pyrogen detection
Science and technology company, Merck, has announced a collaboration with Swiss contract research and service provider, Solvias, for a new monocyte activation test (MAT) kit for pyrogen detection. Read more
EMA approves Lynparza tablets for treatment of platinum-sensitive ovarian cancer
The European Medicines Agency (EMA) has approved AstraZeneca and Merck’s Lynparza (olaparib) tablets as maintenance therapy for the treatment of platinum-sensitive relapsed ovarian cancer, regardless of BRCA status. Read more
Making it count: Key innovations on show at this year’s Interphex meeting, day 1
With a spring in their step, manufacturing experts from pharma and biotech descend on New York to enjoy the offerings from this year’s Interphex meeting. Here’s our brief round-up of what to see from exhibitors at the event on day one… Read more
Merck to partner with Jenner Institute to speed up vaccine availability
Science and technology company, Merck, has partnered with Oxford University’s Jenner Institute to develop cost-effective vaccine manufacturing processes, aimed at speeding up vaccine availability. Read more
Merck collaborates with Medisafe on digital offering to help with adherence
Merck has revealed its collaboration with US-based Medisafe, which is aimed at helping cardiometabolic patients better manage medication intake and adherence to prescribed treatment regimens through a digital offering. Read more
Merck wins Best Bioprocessing Supplier award for second year running
Science and technology company, Merck, has been named as the overall ‘Best Bioprocessing Supplier’ at the Asia-Pacific Bioprocessing Excellence Awards where it also won the sub-category of ‘Best Bioprocessing Supplier Award for Single-use Systems’. Read more
Cladribine tablets now available for certain Scottish patients with MS
The Scottish Medicines Consortium (SMC) has issued its final advice, recommending restricted use of cladribine tablets (Mavenclad, Merck) for the treatment of highly active relapsing multiple sclerosis (MS). Read more
Merck set to be top in pharma licensing deals for 2018, according to GlobalData
Data and analytics company, GlobalData, has revealed its prediction that Merck will lead the way in licensing deals for the year when considering the success of the company since 2016. Read more
CE-marked liquid biopsy tests launched by Biocartis
Two CE-marked IVD liquid biopsy tests have been launched by molecular diagnostics company, Biocartis Group. — the Idylla ctKRAS Mutation Test and the Idylla ctNRAS-BRAF Mutation Test. Read more
MSD to make landmark investment in UK economy with launch of UK hub
Ahead of the government’s announcement of its industrial strategy, it has been revealed that MSD (also known as Merck) will make a landmark investment into the UK’s economy through the opening of a new UK hub, for the research into future treatments. Read more
